Kineta, Children’s join in pediatric clinical-trial effort
Source: Seattle Times
Seattle biotechnology company Kineta and Seattle Children’s Research Institute are joining in an effort to improve development and testing of therapies for pediatric autoimmune diseases. Their collaboration, called Alliance for Children’s Therapeutics, will be funded both by philanthropic gifts to the research institute and equity investments in Kineta. Its initial aim is to raise $1.5 million and conduct clinical trials of a Kineta drug in treating childhood-onset lupus nephritis, a spokesman said. Researchers say clinical trials of new drugs typically don’t include children, creating uncertainty about the effects and dosages.
About Seattle Children’s
Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.
Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.
For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.